OR WAIT null SECS
Examining the State of Biopharma Investment
Understanding is crucial to ensure the right balance in manufacturing technologies and proccesses is achieved.
Obstacles remain before broader application of intensified processes can be implemented.
Limitations in production platforms have impeded continuous manufacturing for advanced therapies.
Considering the differences between small- and large-molecule drug products can help determine analytical testing methods for E&L.
Challenges, Sustainability, and Big Trends in Outsourcing Today
June 09, 2023
This will allow industry leaders to make and sell the product, in addition to providing more choice to pharma and biotech companies.
June 08, 2023
BIO is a powerful business development conference that can help make a lot of deals become reality.
The collaboration between Samsung Biologics and Pfizer will focus on long-term biosimilars manufacturing.
The complaint alleges that Medicaid price controls implemented in the Inflation Reduction Act will negatively impact biopharmaceutical innovation.
Sartorius and Waters will collaborate to develop integrated analytical solutions for downstream biomanufacturing.
The document builds on key concepts outlined in ICH E8(R1) General Considerations for Clinical Studies.
June 07, 2023
Domino Data Labs’ expanded platform includes a new project hub, additional cloud offerings, and the Model Sentry solution suite.
Under the €35 million (US$37 million) investment, MilliporeSigma will expand its sites in Glasgow and Stirling, Scotland, to increase biosafety testing for drug development and commercialization.
June 06, 2023
invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.
Lonza will gain access to R&D capabilities, including payload and site-specific linker technology, through its acquisition of ADC company, Synaffix.